2.50
Hdl Handle:
http://hdl.handle.net/10541/97135
Title:
Intensive combined-modality therapy in small cell lung cancer.
Authors:
Thatcher, Nick; Lorigan, Paul C ( 0000-0002-8875-2164 ) ; Burt, Paul A; Stout, Ronald
Abstract:
Combination ifosfamide/carboplatin/etoposide (ICE) chemotherapy and ICE plus mid-cycle vincristine (VICE) are reviewed. Thoracic radiotherapy and prophylactic cranial irradiation given as single fractions in the majority of patients have been intercalated with VICE in the later studies. The patient populations have not been intensively staged with computed tomography, etc, but do have reasonable Karnofsky performance status ratings and biochemical screens. A policy of no dose reduction over six courses of VICE chemotherapy has been followed in three consecutive studies of 166 patients. The minimum length of follow-up is 26 months and the 2-year survival rate is > or = 30%. Hematopoietic growth factor support in an attempt to overcome the considerable myelosuppression with VICE therapy is currently being evaluated.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
Intensive combined-modality therapy in small cell lung cancer. 1994, 21 (3 Suppl 6):9-22 Semin. Oncol.
Journal:
Seminars in Oncology
Issue Date:
Jun-1994
URI:
http://hdl.handle.net/10541/97135
PubMed ID:
8052879
Type:
Article
Language:
en
ISSN:
0093-7754
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorLorigan, Paul Cen
dc.contributor.authorBurt, Paul Aen
dc.contributor.authorStout, Ronalden
dc.date.accessioned2010-04-22T09:37:56Z-
dc.date.available2010-04-22T09:37:56Z-
dc.date.issued1994-06-
dc.identifier.citationIntensive combined-modality therapy in small cell lung cancer. 1994, 21 (3 Suppl 6):9-22 Semin. Oncol.en
dc.identifier.issn0093-7754-
dc.identifier.pmid8052879-
dc.identifier.urihttp://hdl.handle.net/10541/97135-
dc.description.abstractCombination ifosfamide/carboplatin/etoposide (ICE) chemotherapy and ICE plus mid-cycle vincristine (VICE) are reviewed. Thoracic radiotherapy and prophylactic cranial irradiation given as single fractions in the majority of patients have been intercalated with VICE in the later studies. The patient populations have not been intensively staged with computed tomography, etc, but do have reasonable Karnofsky performance status ratings and biochemical screens. A policy of no dose reduction over six courses of VICE chemotherapy has been followed in three consecutive studies of 166 patients. The minimum length of follow-up is 26 months and the 2-year survival rate is > or = 30%. Hematopoietic growth factor support in an attempt to overcome the considerable myelosuppression with VICE therapy is currently being evaluated.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarboplatin-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshCisplatin-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshEtoposide-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshLung Neoplasms-
dc.subject.meshVincristine-
dc.titleIntensive combined-modality therapy in small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalSeminars in Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.